Literature DB >> 18068270

Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid.

Dorothea Strozyk1, Lenore J Launer, Paul A Adlard, Robert A Cherny, Andrew Tsatsanis, Irene Volitakis, Kaj Blennow, Helen Petrovitch, Lon R White, Ashley I Bush.   

Abstract

Abnormal interaction of beta-amyloid 42 (Abeta42) with copper, zinc and iron induce peptide aggregation and oxidation in Alzheimer's disease (AD). However, in health, Abeta degradation is mediated by extracellular metalloproteinases, neprilysin, insulin degrading enzyme (IDE) and matrix metalloproteinases. We investigated the relationship between levels of Abeta and biological metals in CSF. We assayed CSF copper, zinc, other metals and Abeta42 in ventricular autopsy samples of Japanese American men (N=131) from the population-based Honolulu Asia Aging Study. There was a significant inverse correlation of CSF Abeta42 with copper, zinc, iron, manganese and chromium. The association was particularly strong in the subgroup with high levels of both zinc and copper. Selenium and aluminum levels were not associated to CSF Abeta42. In vitro, the degradation of synthetic Abeta substrate added to CSF was markedly accelerated by low levels (2microM) of exogenous zinc and copper. While excessive interaction with copper and zinc may induce neocortical Abeta precipitation in AD, soluble Abeta degradation is normally promoted by physiological copper and zinc concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068270      PMCID: PMC2709821          DOI: 10.1016/j.neurobiolaging.2007.10.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  42 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

3.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

4.  Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.

Authors:  Anthony R White; Tai Du; Katrina M Laughton; Irene Volitakis; Robyn A Sharples; Michel E Xilinas; David E Hoke; R M Damian Holsinger; Geneviève Evin; Robert A Cherny; Andrew F Hill; Kevin J Barnham; Qiao-Xin Li; Ashley I Bush; Colin L Masters
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

5.  Elevated cortical zinc in Alzheimer disease.

Authors:  D Religa; D Strozyk; R A Cherny; I Volitakis; V Haroutunian; B Winblad; J Naslund; A I Bush
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

6.  Treatment of Alzheimer's disease with clioquinol.

Authors:  B Regland; W Lehmann; I Abedini; K Blennow; M Jonsson; I Karlsson; M Sjögren; A Wallin; M Xilinas; C G Gottfries
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Nov-Dec       Impact factor: 2.959

7.  Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc.

Authors:  A M Brown; D M Tummolo; K J Rhodes; J R Hofmann; J S Jacobsen; J Sonnenberg-Reines
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

8.  Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.

Authors:  Carlos Opazo; Sandra Luza; Victor L Villemagne; Irene Volitakis; Christopher Rowe; Kevin J Barnham; Dorothea Strozyk; Colin L Masters; Robert A Cherny; Ashley I Bush
Journal:  Aging Cell       Date:  2006-02       Impact factor: 9.304

9.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

Authors:  X Huang; M P Cuajungco; C S Atwood; M A Hartshorn; J D Tyndall; G R Hanson; K C Stokes; M Leopold; G Multhaup; L E Goldstein; R C Scarpa; A J Saunders; J Lim; R D Moir; C Glabe; E F Bowden; C L Masters; D P Fairlie; R E Tanzi; A I Bush
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

10.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

Authors:  Carlos Opazo; Xudong Huang; Robert A Cherny; Robert D Moir; Alex E Roher; Anthony R White; Roberto Cappai; Colin L Masters; Rudolph E Tanzi; Nibaldo C Inestrosa; Ashley I Bush
Journal:  J Biol Chem       Date:  2002-08-20       Impact factor: 5.157

View more
  37 in total

1.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 2.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

3.  Functional relevance of a novel SlyX motif in non-conventional secretion of insulin-degrading enzyme.

Authors:  Konstantin Glebov; Sebastian Schütze; Jochen Walter
Journal:  J Biol Chem       Date:  2011-05-16       Impact factor: 5.157

4.  Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production.

Authors:  Hermeto Gerber; Fang Wu; Mitko Dimitrov; Guillermo M Garcia Osuna; Patrick C Fraering
Journal:  J Biol Chem       Date:  2017-01-17       Impact factor: 5.157

5.  Regulation of copper transport crossing brain barrier systems by Cu-ATPases: effect of manganese exposure.

Authors:  Xue Fu; Yanshu Zhang; Wendy Jiang; Andrew Donald Monnot; Christopher Alexander Bates; Wei Zheng
Journal:  Toxicol Sci       Date:  2014-03-10       Impact factor: 4.849

6.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

Review 7.  Regulation and function of selenoproteins in human disease.

Authors:  Frederick P Bellinger; Arjun V Raman; Mariclair A Reeves; Marla J Berry
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

Review 8.  A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease.

Authors:  Mark A Lovell
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice.

Authors:  Christa J Maynard; Roberto Cappai; Irene Volitakis; Katrina M Laughton; Colin L Masters; Ashley I Bush; Qiao-Xin Li
Journal:  Cell Mol Neurobiol       Date:  2009-04-21       Impact factor: 5.046

Review 10.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.